Table 2. Adverse events occurring during MDR-TB treatment.
| Adverse event | AEa n (%) (N = 659) | SAEb n (%) (N = 659) |
|---|---|---|
| At least one adverse event | 470 (71.3) | 115 (17.5) |
| Gastrointestinal disorders | 254 (38.5) | 18 (2.7) |
| Arthralgia | 229 (34.7) | 5 (0.8) |
| Psychiatric disorders | 222 (33.7) | 18 (2.7) |
| Central nervous system disorders | 198 (30.0) | 18 (2.7) |
| Hyperuricemia | 193 (29.3) | 4 (0.6) |
| Dermatologic reactions | 119 (18.1) | 4 (0.6) |
| Hearing loss or vestibular disorders | 100 (15.2) | 24 (3.6) |
| Visual impairment | 69 (10.5) | 22 (3.3) |
| Hypokalaemia | 60 (9.1) | 3 (0.5) |
| Peripheral neuropathy | 52 (7.9) | 1 (0.2) |
| Nephrotoxicity | 49 (7.4) | 10 (1.5) |
| Glucose metabolism disorders | 42 (6.4) | 18 (2.7) |
| Hepatoxicity | 38 (5.8) | 12 (1.8) |
| Hematologic disorders | 23 (3.5) | 4 (0.6) |
| Anaphylactic reactions | 4 (0.6) | 2 (0.3) |
| Hypothyroidism (n = 263)c | 3 (1.1) | 0 (0) |
AEa: Adverse Event.
SAEb: Serious Adverse Event.
Hypothyroidism (n = 263)c: 263 patients had thyroid-stimulating hormone results at baseline and at least one measurement during the treatment.